

ADDEX THERAPEUTICS LIMITED SPON ADS EACH REP 120 ORD

ISIN: US00654J2069 WKN: 00654J206 Asset Class: Stock

Company



2024/04/16 22:00:00

Price

22.60

USD

Difference

-8.69% (-2.15)



Contact Details

ADDEX THERAPEUTICS LTD.

Tel: +41-22-884-15-55

--

Fax: +41-22-884-15-56

9, Chemin des Mines,
Plan-les-Ouates

Web:
<http://www.addextherapeutics.com>

1202 Genf

E-mail:
info@addextherapeutics.com

Company Profile

Addex Therapeutics Ltd. is a biopharmaceutical company, which engages in the development of drugs for human health. It develops novel, orally available, and small molecule allosteric modulators for neurological disorders. Its pipeline includes Dipraglurant, ADX71149, GABAB PAM, mGlu7 NAM, mGlu2 NAM, mGlu4 PAM, and mGlu3 PAM. The company was founded by Vincent Mutel, Timothy Dyer, and Mark Epping-Jordan in 2002 and is headquartered in Geneva, Switzerland.

Financial figures, Fiscal year: from 01.01. to 31.12.

Financial figures	2022		2021		2020	
	Assets	Liabilities and equity	Assets	Liabilities and equity	Assets	Liabilities and equity
Current assets	7,825,000		21,924,000		19,261,000	
Common stock capital		1,153,000		49,272,000		32,848,000
Fixed assets	453,000		600,000		855,000	
Equity capital of a company		4,909,000		16,913,000		14,544,000
Cash and cash equivalents	6,957,000		20,484,000		18,695,000	
Accrued liabilities		0		1,281,000		1,692,000
Other assets	-		-		-	
Current liabilities		3,282,000		4,134,000		3,620,000
Prepayments and accrued income	-		-		-	
Non-current liabilities		87,000		1,475,000		1,951,000
Different income		-		-		-
Other liabilities		0		0		0
Total assets	8,278,000	8,278,000	22,524,000	22,524,000	20,116,000	20,116,000

Balance notes

	2022	2021	2020
Accounting standard	IFRS	IFRS	IFRS
Employees	24	28	27
Equity ratio	59.30%	75.09%	72.30%
Debt-equity ratio	68.62%	33.17%	38.31%

Others

	2022	2021	2020
Tax Expense Rate	0.00%	0.00%	0.00%

ADDEX THERAPEUTICS LIMITED SPON ADS EACH REP 120 ORD

ISIN: US00654J2069 WKN: 00654J206 Asset Class: Stock

Income statement

	2022	2021	2020
Turnover	1,444,000	2,934,000	3,634,000
Net income	-20,804,000	-15,351,000	-12,858,000
EBIT	-21,366,535	-15,722,462	-13,183,484
Operating income before taxes	-20,804,000	-15,351,000	-12,858,000
Cash Flow	-16,456,000	-14,762,000	-12,214,000
Net interest income	-19,000	-57,000	-34,000
Research and development expenses	14,447,000	12,567,000	10,070,000
Income taxes	0	0	0
Result from investments in subsidiaries, associates and other	0	0	0
Revenues per employee	61,892	107,756	138,393

Board of Directors

Isaac Manke	Member of the administrative board
Raymond Hill	Member of the administrative board
Roger Mills	Member of the administrative board
Jake Nunn	Member of the administrative board
Vincent Lawton	Chairman of the administrative board

Members of Management Board

Tim Dyer	Chairman of Managing Board
Jean-Philippe Rocher	Member of Executive Committee
Mikhail Kalinichev	Member of Executive Committee
Robert Lütjens	Member of Executive Committee
Roger G. Mills	Member of Executive Committee